Praxis Precision Medicines to Showcase Innovative Therapies at Upcoming Conferences

Praxis Precision Medicines to Participate in Upcoming April Conferences

April 3, 2025 - - Praxis Precision Medicines, a clinical-stage biotech company focused on developing novel precision medicines, today announced that it will be participating in two upcoming conferences in April.

The company will be presenting at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-14 in New Orleans. The presentation will focus on the company's lead candidate, PRX-115, a novel, small-molecule inhibitor of the protein-tyrosine phosphatase, SHP2, which is being developed for the treatment of various cancers.

Additionally, Praxis Precision Medicines will be participating in the 2025 Investor Summit on Healthcare, taking place April 15-16 in New York City. The company's leadership team will be available for one-on-one meetings with investors and analysts to discuss the company's progress and vision for the future.

"We are excited to be participating in these two prominent conferences, which provide a great opportunity for us to share our progress with the scientific and investment communities," said [Name], CEO of Praxis Precision Medicines. "We believe that our precision medicine approach has the potential to make a significant impact in the treatment of various diseases, and we look forward to discussing our plans and progress with attendees."

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biotech company focused on developing novel precision medicines for the treatment of various diseases. The company's lead candidate, PRX-115, is a novel, small-molecule inhibitor of the protein-tyrosine phosphatase, SHP2, which is being developed for the treatment of various cancers. Praxis Precision Medicines is headquartered in [City].